ABSTRACT
There are few options for prophylaxis after exposure to Bacillus anthracis, especially in children and women of childbearing potential. Faropenem is a beta-lactam in the penem subclass that is being developed as an oral prodrug, faropenem medoxomil, for the treatment of respiratory tract infections. Faropenem was shown to have in vitro activity against B. anthracis strains that variably express the bla1 beta-lactamase (MIC range, Subject(s)
Anthrax/drug therapy
, Anthrax/prevention & control
, Anti-Bacterial Agents/pharmacokinetics
, Bacillus anthracis/drug effects
, beta-Lactams/pharmacokinetics
, Animals
, Anthrax/mortality
, Anti-Bacterial Agents/blood
, Blood Proteins/metabolism
, Disease Models, Animal
, Dose-Response Relationship, Drug
, Female
, Inhalation Exposure
, Mice
, Mice, Inbred BALB C
, Models, Biological
, beta-Lactamases/metabolism
, beta-Lactams/blood